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Highlights 
x Ceftaroline fosamil treatment in patients with ABSSSI and sepsis 
x Post hoc analysis of patients given 600 mg ceftaroline fosamil q12h or q8h 
x Clinical cure rates were comparable for both ceftaroline fosamil dosage regimens 
x Ceftaroline exposures were not affected by disease severity 
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Abstract (word count 250/250) 
Background: Post-hoc analysis compared pharmacokinetics and clinical outcomes of 
ceftaroline fosamil 600 mg every 12 (q12h) versus every 8 hours (q8h), in patients with 
acute bacterial skin and skin structure infections (ABSSSI) and signs of sepsis. 
Methods: Clinical outcomes at test-of-cure in patients with ABSSSI and systemic 
inflammatory signs/systemic inflammatory response (SIRS), and ceftaroline minimum 
inhibitory concentrations (MICs) against baseline pathogens were compared between 
COVERS (ceftaroline fosamil 600 mg q8h, 2-h infusion) and the CANVAS 1 and 2 trials 
(ceftaroline fosamil 600 mg q12h, 1-h infusion). Ceftaroline exposures among patients in 
COVERS with or without markers of sepsis were compared using population 
pharmacokinetic (PK) modeling.  
Results: In COVERS, 62% (312/506) and 41% (208/506) of ceftaroline fosamil-treated 
patients had ≥1 systemic sign or SIRS, respectively and 55% (378/693) and 22% 
(152/693), respectively in the CANVAS trials. Clinical cure rates for the modified intent-
to-treat (MITT) population in COVERS and CANVAS were similar for ceftaroline 
fosamil-treated patients with ≥1 sign of sepsis (82% [255/312] and 85% [335/394]) and 
for those with SIRS (84% [168/199] and 85% [131/155]). Ceftaroline MIC distributions 
were similar across trials. Sepsis did not affect predicted individual steady-state 
ceftaroline exposures. 
Conclusions: Clinical cure rates in patients with ≥1 systemic inflammatory sign or SIRS 
were comparable for both ceftaroline fosamil dosage regimens. Pathogen susceptibilities 
to ceftaroline were similar across trials. Ceftaroline exposures were not affected by 
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disease severity. Ceftaroline fosamil 600 mg q12h is a robust dosage regimen for most 
ABSSSI patients with sepsis. 
Trial Registry Information: https://clinicaltrials.gov: (NCT01499277, NCT00424190, 
NCT00423657).  
Keyword(s): ceftaroline fosamil; skin and soft tissue infection; sepsis; clinical trial  
 
 
 
1. Introduction (Word count=3130/4000) 
Acute bacterial skin and skin structure infection (ABSSSI) and complicated skin and soft 
tissue infection (cSSTI) include cellulitis/erysipelas, wound infection, and major 
cutaneous abscess [1, 2] and impose a substantial burden on healthcare systems. Between 
2005 and 2010, the incidence of skin and soft tissue infection in the United States was 
approximately 48 per 1000 person-years [3]; currently, up to 300,000 surgical site 
infections occur each year, including those in skin and subcutaneous tissue [4]. Skin and 
soft tissue infections can be serious, requiring hospitalization and surgical procedures, 
and occasionally can cause bacteremia and death [5]. Factors associated with ABSSSI 
onset and clinical failures of ABSSSI treatment include obesity and low antibiotic dosage 
at discharge [6, 7]. 
Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin 
antibiotic with in vitro activity against many of the common bacteria associated with 
ABSSSI, including S. aureus (both methicillin-susceptible [MSSA] and methicillin-
resistant [MRSA]), Streptococcus pyogenes, Streptococcus agalactiae, and non-ESBL 
producing Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca [8, 9]. In the 
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pivotal phase III CANVAS 1 and 2 trials, ceftaroline fosamil 600 mg given as a 1 hour 
IV infusion every 12 hours (q12h) was shown to be non-inferior to vancomycin plus 
aztreonam for the treatment of ABSSSI [10-12]. These results supported the US Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) approvals of 
ceftaroline fosamil 600 mg q12h (adjusted for renal function) for the treatment of adults 
with ABSSSI and cSSTI, respectively [8, 9]. 
The presence of sepsis can impact the pharmacokinetics (PK) of some antibiotics and 
thus potentially affect antibiotic efficacy in patients with ABSSSI. Septic patients in the 
intensive care unit have shown increased volume of distribution and increased clearance. 
An increase in volume of distribution in these patients has been shown to be due to 
capillary leak and endothelial damage, which can result in sub-therapeutic dosing 
following administration of antibiotics. Clearance is variable and is dependent on the 
individual’s disease state. Variable exposure to drug as a result of changes in volumes 
and clearance can, in turn, result in variable responsiveness to treatment, in terms of both 
efficacy and toxicity, and this can impact mortality rates in these patients [13-15]. 
The phase III COVERS trial was conducted to assess a ceftaroline fosamil dosage 
regimen of 600 mg as a 2 hour infusion every 8 hours (q8h) in patients with ABSSSI with 
systemic inflammatory response syndrome (SIRS) or underlying comorbidities and, on 
average, a greater lesion size [12]. Results from COVERS showed that ceftaroline 
fosamil 600 mg q8h was non-inferior to vancomycin plus aztreonam in these patients 
[12]. The objective of this post hoc analysis was to compare ceftaroline fosamil 600 mg 
q12h versus 600 mg q8h for the treatment of ABSSSI in patients with signs of sepsis, 
firstly by comparing clinical outcomes and pathogen susceptibilities in the COVERS trial 
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with the previously published CANVAS trials, and secondly by using population PK 
modeling to compare ceftaroline exposures in patients with or without markers of sepsis. 
2. Material and Methods 
2.1. Study Design  
COVERS (NCT01499277) and CANVAS 1 and 2 (NCT00424190 and NCT00423657) 
were phase 3, multicenter, randomized, double-blind, comparative safety and efficacy 
trials of IV ceftaroline fosamil versus vancomycin plus aztreonam for the treatment of 
ABSSSI [10-12]. Patients were randomized to receive ceftaroline fosamil or vancomycin 
plus aztreonam at a ratio of 2:1 in COVERS and 1:1 in CANVAS 1 and 2. In COVERS, 
ceftaroline fosamil was administered at 600 mg q8h and vancomycin was administered at 
15 mg/kg q12h with aztreonam at 1 g q8h. In CANVAS 1 and 2, ceftaroline fosamil was 
administered at 600 mg q12h and vancomycin plus aztreonam were each administered at 
1 g q12h. Ceftaroline fosamil dosages were adjusted for patients with baseline creatinine 
clearance (CrCl) ≤50 mL/min and vancomycin plus aztreonam dosages were adjusted 
according to respective product labelling and institutional practice guidelines. Treatments 
were given for 5–14 days in all trials. The primary outcome measure for all three trials 
was clinical cure rate at test-of-cure (TOC) in the modified intent-to-treat (MITT) and 
clinically evaluable (CE) patient populations. 
2.2. Patient and Disease Characteristics 
The COVERS and CANVAS trials enrolled adult patients with cSSTI. The entire 
COVERS patient population, and a proportion of those in the CANVAS trials, met the 
FDA definition of ABSSSI [1]. Inclusion and exclusion criteria for the CANVAS trials 
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have been described previously [10, 11]; in brief, patients had a diagnosis of cSSTI 
(defined as deep extensive cellulitis, major cutaneous abscess requiring surgical drainage, 
or infected wound, ulcer or burn) of sufficient severity to warrant hospitalization and ≥5 
days of parenteral antibacterial therapy. Inclusion and exclusion criteria for COVERS 
were similar to the CANVAS trials, with an additional requirement of ABSSSI with 
surrounding area of erythema, edema, and/or induration with surface area ≥75 cm2, 
reflecting regulatory guidance at the time the study was initiated [1, 12]; of note, 
COVERS (but not CANVAS) excluded patients with diabetic foot infections. Disease 
characteristics assessed at baseline included systemic signs of infection, presence of SIRS 
(defined as presence of ≥2 of the following symptoms at baseline: temperature <36°C or 
>38°C; heart rate >90 beats per minute; respiratory rate >20 breaths per minute, or on 
blood gas, a PaCO2 <32 mmHg [4.3 kPa]; white blood cells [WBCs] <4000 cells/mm3 or 
>12,000 cells/mm3, or >10% band forms [immature WBC]), and elevated C-reactive 
protein (CRP) levels. Patients were required to give informed consent prior to enrolment 
in the trials. 
2.3. Microbiology 
Baseline pathogen susceptibilities to ceftaroline (minimum inhibitory concentrations 
[MICs]) were determined using Clinical and Laboratory Standards Institute methodology 
[16] by a central reference laboratory.  
2.4. Clinical Outcomes 
Clinical cure was defined as the total resolution of all signs and symptoms of the baseline 
infection or improvement such that no further antimicrobial therapy was necessary. 
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Outcome was determined at the TOC time point (8–15 days after the last dose of study 
drug) in the MITT population (all randomized patients that received any study 
medication) and CE population, a subset of the MITT population that had a diagnosis of 
ABSSSI, had no non-eligible infections, received a prespecified minimum of study drug, 
had an evaluation at the TOC (or were determined to be a clinical failure at end of 
therapy), and did not receive any systemically active antibacterial agents that may have 
affected the infection under study [12, 17]. Clinical cure rates were summarized for the 
MITT and CE populations overall, and for patient subgroups with ≥1 systemic sign of 
inflammation, or sepsis (fever >38°C, hypothermia <36°C, elevated WBC count 
[>10,000 cells/mm3 or bands >10%]), ≥2 severe signs or symptoms (erythema, swelling, 
tenderness, or warmth that was designated as “severe” by the investigator) or SIRS. As 
body weight and renal function have also been shown to impact ceftaroline PK [18, 19], 
clinical cure rates were summarized by body mass index (BMI) and CrCl to compare 
outcomes across BMI and CrCl subgroups. Finally, clinical cure rates were also 
summarised by baseline pathogen. Safety was assessed in all randomized patients who 
received ≥1 dose of study therapy. 
2.5. Population Pharmacokinetic Modeling 
The ceftaroline population PK model used in this analysis was developed using a large 
patient PK dataset, which included data from 14 phase I trials in healthy subjects (with 
normal renal function or renal impairment), one phase II trial in patients with cSSTI, 
three phase III trials in patients with cSSTI (CANVAS 1, CANVAS 2, and COVERS) 
and three phase III trials in patients with community-acquired pneumonia [10-12, 19-28]. 
Patient PK data were obtained in COVERS, and in a subset of 45 patients in CANVAS 1 
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and 2 trials, by sparse PK sampling over a single dosing interval (ie 8 hours) on Day 3, 
with intensive PK samples taken in a subset of patients [29]. The population PK model 
was derived from first-order conditional estimation with the interaction model using the 
software program, NONMEM version 7.2.0 (ICON plc, Dublin, Ireland). Details related 
to the PK modeling have been previously described [30]. Ceftaroline PK profiles were 
estimated for individual patients in COVERS with available ceftaroline PK data. Steady 
state ceftaroline exposures (maximum plasma concentration [Cmax, ss] and area under the 
curve [AUCss]) were derived from the individual predicted ceftaroline concentration-time 
courses from the population PK model using noncompartmental analysis. To assess 
whether the presence of markers of systemic inflammation, or sepsis, had any impact on 
ceftaroline exposures, AUCss and Cmax,ss were compared for the following patient 
subgroups: fever ≤38°C or >38°C, WBC ≤12,000/mm3 or >12,000/mm3, CRP ≤50 mg/L, 
>50 to ≤150 mg/L or >150 mg/L, and presence or absence of SIRS or bacteremia at 
baseline [29]. 
2.6. Statistical Analyses 
Patient outcomes are presented using descriptive statistics and between-group outcome 
differences (95% CI) were determined using the Miettinen and Nurminen method [31]. 
Full details of the statistical analyses used in the COVERS and CANVAS 1 and 2 trials 
have previously been described [10, 11]. 
3. Results 
3.1. Patient Demographics and Baseline Characteristics 
Patient demographics and baseline characteristics are summarized in Table 1. Most 
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patients were male and white. Overall, baseline characteristics, including body mass 
index, comorbidities, and prior antibiotic therapy, were similar between the patient 
populations in COVERS and the CANVAS trials. Patients were slightly older in 
COVERS compared with the CANVAS trials (mean age [SD], 52.6 [16.5] years vs 47.5 
[17.0] years for ceftaroline fosamil-treated patients) and there was a greater proportion of 
patients with a primary cSSTI diagnosis of cellulitis in COVERS (300 [59.3%] vs 249 
[35.9%] for ceftaroline fosamil-treated patients).  
As expected based on inclusion criteria, more severe ABSSSI was observed in patients in 
COVERS; median (range) infection area was greater among ceftaroline fosamil−treated 
patients from COVERS compared with those from CANVAS 1 and 2 (400 [75–5040] 
cm2 in COVERS vs 156 [1–3150] cm2 in CANVAS 1 and 2). A greater proportion of 
ceftaroline fosamil−treated patients from COVERS also had ≥1 systemic inflammatory 
sign (312/506 [61.7%] COVERS vs 378/693 [54.5%] CANVAS 1 and 2) and SIRS 
(208/506 [41.1%] COVERS vs 152/693 [21.9%] CANVAS 1 and 2) at baseline. 
Compared with CANVAS 1 and 2, a greater proportion of patients in COVERS had 
elevated baseline C-reactive protein levels. 
3.2. Baseline Pathogens 
The most common pathogens isolated at baseline in the COVERS patient population 
were MSSA (n=164 [39%]), MRSA (n=54 [13%]), non−extended-spectrum beta-
lactamase-producing E. coli (n=26 [6%]), and S. pyogenes (n=25 [6%]). In the CANVAS 
trials, MSSA (n=244 [38%]), MRSA (n=164 [25%]), S. pyogenes (n=61 [9%]), and 
Enterococcus faecalis (n=27 [4%]) were most commonly isolated. The proportion of 
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patients with no baseline pathogen identified was higher in COVERS (n=378 [49.0%]) 
compared to the CANVAS trials (n=324 [23.2%]), reflecting the higher proportion of 
patients with cellulitis in the COVERS trial. 
Ceftaroline susceptibilities of pathogens isolated at baseline were generally similar 
between the COVERS and CANVAS trials (Table 2). In both COVERS and the 
CANVAS trials, the ceftaroline MIC (range) and MIC90 for MSSA isolates were 0.06 to 
0.5 mg/L, and 0.25 mg/L, respectively. Ceftaroline susceptibility among MRSA isolates 
were as follows: COVERS MIC (range), MIC90, 0.25–1.0 mg/L, 0.5 mg/L; CANVAS 
MIC (range), MIC90, 0.25–2.0 mg/L, 0.5 mg/L. Ceftaroline MIC (range) and MIC90 of S. 
pyogenes isolates from COVERS were both ≤0.008; ceftaroline MIC (range) and MIC90 
of S. pyogenes isolates from the CANVAS trials were <0.004 to 0.0008 mg/L and ≤0.004 
mg/L, respectively. 
3.3. Clinical Outcomes (MITT population) 
Overall clinical cure rates at TOC for ceftaroline fosamil were 78.3% (396/506) in the 
COVERS trial and 85.9% (595/693) in the CANVAS trials. For patients treated with 
vancomycin plus aztreonam, overall clinical cure rates were 79.2% (202/255) in the 
COVERS trial and 85.5% (586/685) in the CANVAS trials. Clinical cure rates by 
inflammatory sign, BMI and CrCl subgroups and overall are summarized in Table 3. 
Clinical cure rates for ceftaroline fosamil−treated patients across all subgroups with 
systemic inflammatory signs or SIRS were broadly similar in the COVERS and 
CANVAS trials, ranging from 79% to 85% in COVERS and from 83% to 89% in the 
CANVAS trials. For comparison, the clinical cure rates for vancomycin plus aztreonam 
ranged from 72% to 88% in the COVERS trial and from 84% to 90% in the CANVAS 
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trials. Among ceftaroline fosamil−treated patients with ≥1 systemic sign of inflammation, 
or sepsis, clinical cure was observed in 81.7% (255/312) patients in COVERS and 85.0% 
(335/394) patients in CANVAS 1 and 2. Among ceftaroline fosamil−treated patients with 
SIRS, clinical cure was observed in 84.4% (168/199) from COVERS and 84.5% 
(131/155) from CANVAS 1 and 2. Clinical cure rates by inflammatory sign and overall 
for the CE population were similar to those in the MITT (Supplemental Table 1). 
Clinical cure rates were generally comparable between ceftaroline fosamil-treated BMI 
subgroups in the COVERS and CANVAS trials, with the exception of a small number of 
patients with BMI <18.5 kg/m2 (clinical cure rate 8/15 [53.3%] in COVERS compared 
with 11/15 [73.3%] in CANVAS). Clinical cure rates for ceftaroline fosamil-treated 
patient subgroups with BMI ≥18.5 –<25, ≥25–<30 and ≥30 kg/m2 ranged from 75.2% to 
84.5% in COVERS and 84.5% to 91.2% in the CANVAS trials. A small proportion of 
ceftaroline fosamil-treated patients had moderate renal impairment (CrCl >30-≤50 
mL/min) at baseline in the COVERS and CANVAS trials (31 [6.1%] and 23 [3.3%] 
respectively). Clinical cure rates for ceftaroline fosamil-treated patients with moderate 
renal impairment were 23/31 (74.2%) in COVERS and 19/23 (82.6%) in the CANVAS 
trials. Clinical cure rates for BMI and CrCl subgroups in the CE population were similar 
to those in the MITT (Supplemental Table 1). 
Clinical cure rates by baseline pathogen (ME population) are summarized in Table 4. 
Among ceftaroline fosamil−treated patients with infections caused by MSSA, clinical 
cure rates were 93.6% (88/94) and 93.0% (212/228) in COVERS and CANVAS 1 and 2, 
respectively. Clinical cure was observed 84.0% (21/25) and 93.4% (142/152)  of 
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ceftaroline fosamil−treated patients with infections caused by MRSA from COVERS and 
CANVAS 1 and 2, respectively; all MRSA isolates from COVERS and CANVAS 1 and 
2 had a ceftaroline MIC of ≤1 mg/L and ≤2 mg/L, respectively.  
3.4. Safety 
In COVERS, 45.8% (232/506) of patients treated with ceftaroline fosamil experienced ≥1 
adverse event (AE) compared with 45.5% (116/255) of patients treated with vancomycin 
plus aztreonam; 44.7% (309/692) of patients treated with ceftaroline fosamil and 47.5% 
(326/686) of patients treated with vancomycin plus aztreonam experienced ≥1 AE in the 
CANVAS trials. The most common AEs among ceftaroline fosamil-treated patients in 
COVERS (occurring in ≥3% of patients) were nausea (4.0%), headache (3.4%), and 
hypokalemia (3.0%). The most common AEs among ceftaroline fosamil-treated patients 
in CANVAS 1 and 2 (occurring in ≥3% of patients) were nausea (5.9%), headache 
(5.2%), diarrhea (4.9%), pruritus (3.5%), and rash (3.2%). 
3.5. Population PK Modeling of Ceftaroline Exposures 
Overall, the population PK modeling dataset included data from 951 subjects, of which 
463 were patients with cSSTI. The model described the observed ceftaroline 
concentration data well, and was considered suitable to calculate exposure parameters for 
individual patients in COVERS. PK data were available from 371 patients in COVERS 
for whom a full ceftaroline plasma concentration time-course could be calculated. 
Individual predictions of AUCss and Cmax, ss for these patients are summarised by the 
presence or absence of fever, SIRS or bacteremia, high WBC count and CRP levels in 
Figure 1. The individual, median and range AUCss and Cmax, ss values demonstrated clear 
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evidence of overlap in patients within the respective disease severity parameters, 
indicating that these parameters had little effect on the exposures of ceftaroline. 
4. Discussion 
The COVERS and CANVAS 1 and 2 trials all included patients with systemic signs of 
inflammation, or sepsis, and SIRS, allowing for an informative comparison of the clinical 
outcomes associated with ceftaroline fosamil 600 mg as a 1 hour infusion, q8h, versus 
600 mg as a 2 hour infusion, q12h in patients with severe ABSSSI. Because the 
pathogens isolated and their associated ceftaroline susceptibilities in the COVERS trial 
were similar to the CANVAS trials, we compared the clinical outcomes and pathogen 
susceptibilities. This provides further rationale for the comparison of clinical outcomes 
between the trials. Moreover, a patient-rich population ceftaroline PK model, which 
included data from over 900 subjects, allowed evaluation of predicted ceftaroline 
exposures for patients with and without sepsis, complementing the clinical data 
comparisons between the trials.  
Although the ceftaroline fosamil q8h dosage regimen was efficacious in COVERS, 
clinical outcomes among ceftaroline fosamil–treated patient subgroups with more severe 
disease (ie, >1 systemic sign of inflammation, or sepsis, fever, elevated WBC, or SIRS), 
were comparable to patients receiving ceftaroline fosamil q12h in the CANVAS trials. 
Clinical cure rates were also generally comparable for BMI and CrCl patient subgroups 
in the COVERS and the CANVAS trials. Differences in clinical cure rates for ceftaroline 
fosamil versus vancomycin plus aztreonam were broadly similar across the trials; for both 
treatment groups, clinical cure rates were generally numerically lower in COVERS 
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compared to the CANVAS trials. This is likely due to patients generally having a more 
severe infection and comorbidities that are not captured in a single subgroup category. 
Ceftaroline fosamil was well tolerated in both trials, with AEs representative of the 
cephalosporin class. Hence, the q12h regimen appears robust for the majority of patients 
with ABSSSI, regardless of the presence of systemic inflammatory signs. 
These clinical data are aligned with population PK modeling of individual patients within 
the COVERS trial, which showed that steady state exposures of ceftaroline were 
comparable across patients with and without signs of sepsis. The PK of ceftaroline in 
COVERS were similar to results previously reported for subjects treated with ceftaroline 
fosamil q12h [18, 32], with a dose-proportional increase in exposure from the q8h dosing 
used in COVERS [30, 32, 33]. Ceftaroline PK therefore does not appear to be affected by 
disease severity, suggesting that the ceftaroline fosamil q12h regimen provides adequate 
exposures in ABSSSI patients with severe disease. Pathogen susceptibilities to ceftaroline 
were similar between the COVERS and CANVAS trials, with both dosage regimens 
providing broad coverage against commonly isolated ABSSSI pathogens. The MICs of 
>95% of baseline isolates across the three trials were at or below respective CLSI and 
EUCAST susceptibility breakpoints for ceftaroline fosamil 600 mg q12h [16, 34]. 
Clinical response rates were generally comparable across the COVERS and CANVAS 
trials for key ABSSSI pathogens, including S. aureus. MRSA isolated from COVERS 
and CANVAS 1 and 2 had ceftaroline MICs of ≤1 mg/L and ≤2 mg/L, respectively. 
Probability of target attainment (PTA) analyses using the ceftaroline population PK 
model described above have shown that >95% PTA is predicted with the 600 mg q12h 
dose regimen for S. aureus isolates with MICs up to 2 mg/L [30]. With the 600 mg q8h 
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dosage regimen, >95% PTA is predicted for S. aureus isolates with MICs up to 4 mg/L 
[30]. In 2017, the EMA label was updated to recommend the use of ceftaroline fosamil 
600 mg q8h for cSSTI patients where the causative pathogen is S. aureus with a 
ceftaroline minimum inhibitory concentration (MIC) of 2 or 4 mg/L [8]; such isolates are 
very rare in the US and Europe [35, 36].  
Because individual study patient PK data were not analyzed in this retrospective analysis 
and individual patients may have different states of disease, this was not described in the 
CANVAS and COVERS trials. We believe that confounds that do exist in this particular 
patient population are valid, but given the positive findings in our study, do not appear to 
play a substantial role in the efficacy or toxicity of ceftaroline treatment. In addition, 
because this analysis is a retrospective cross-trial comparison, it is limited by the inability 
to completely control for population differences between trials. Similarly, as enrollment 
for COVERS and the CANVAS trials occurred in different geographic locations, regional 
differences in care may have affected the results. However, given that the population PK 
analyses support the conclusions from the cross-trial comparison, the data overall support 
that ceftaroline fosamil 600 mg q12h is a robust dosage regimen for the great majority of 
patients with ABSSSI, including those with sepsis and SIRS.  
5. Conclusions 
On the basis of the clinical, microbiological and population PK modeling comparisons 
presented here, sepsis did not affect predicted individual steady state ceftaroline 
exposures. Ceftaroline fosamil 600 mg q12h is a well-tolerated, efficacious dosage 
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regimen for the majority of patients with severe ABSSSI, regardless of the extent of 
sepsis.  
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Table 1 
Patient Demographics and Baseline Characteristics (MITT Population) 
 COVERS  CANVAS 1 and 2 
Characteristic 
Ceftaroline Fosamil 
n=506 
Vancomycin Plus 
Aztreonam 
n=255  
Ceftaroline Fosamil 
n=693 
Vancomycin Plus 
Aztreonam 
n=685 
Age, mean (SD), y 52.6 (16.5) 53.6 (16.3)  47.5 (17.0) 48.4 (16.6) 
Sex, n (%)      
Female 196 (38.7) 107 (42.0)  249 (35.9) 266 (38.8) 
Male 310 (61.3) 148 (58.0)  444 (64.1) 419 (61.2) 
Race, n (%)      
White 341 (67.4) 160 (62.7)  506 (73.0) 512 (74.7) 
Black or African American 13 (2.6) 13 (5.1)  48 (6.9)  41 (6.0) 
Asian 126 (24.9) 64 (25.1)  6 (0.9) 5 (0.7) 
American Indian or Alaska Native 1 (0.2) 0  6 (0.9) 4 (0.6) 
Native Hawaiian or Other Pacific – –  2 (0.3) 2 (0.3) 
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Islander 
Multiracial/other 25 (4.9) 18 (7.1)  6 (0.9) 7 (1.0) 
BMI, median (range), kg/m2 26.6 (15.0–50.0) 26.6 (14.0–50.0)  26.9 (14.1–74.1) 27.4 (16.6–66.5) 
Baseline CrCl (mL/min)a      
>30–≤50 31 (6.1) 17 (6.7)  23 (3.3) 26 (3.8) 
>50–≤80 91 (18.0) 46 (18.0)  99 (14.3) 98 (14.3) 
>80 362 (71.5) 183 (71.8)  569 (82.1) 559 (81.6) 
Baseline C-reactive protein, mg/L      
≤50 178 (35.2) 100 (39.2)  396 (57.1) 387 (56.5) 
>50−≤150 178 (35.2) 80 (31.4)  177 (25.5) 166 (24.2) 
>150 139 (27.5) 68 (26.7)  98 (14.1)  111 (16.2) 
Primary diagnosis of cellulitis 300 (59.3) 136 (53.3)  249 (35.9) 273 (39.9) 
Comorbid conditions, n (%)      
Diabetes mellitus 84 (16.6) 38 (14.9)  122 (17.6) 120 (17.5) 
Peripheral vascular disease 27 (5.3) 11 (4.3)  93 (13.4) 93 (13.6) 
Infection area, median (range), cm2 400 (75–5040) 400 (77–6048)  156 (1–3150) 150 (0.04–4950) 
Prior antibiotic therapy, n (%) 240 (47.4) 116 (45.5)  276 (39.8) 260 (38.0) 
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≥1 systemic inflammatory sign, n (%)b 312 (61.7) 166 (65.1)  378 (54.5) 363 (53.0) 
≥2 severe signs and/or symptoms, n (%)c 329 (65.0) 165 (64.7)  372 (53.7) 379 (55.3) 
SIRS, n (%)d 208 (41.1) 113 (44.3)  155 (22.4) 163 (23.8) 
BMI=body mass index; MITT=modified intent-to-treat population; SIRS=systemic inflammatory response syndrome. 
aEight patients had CrCl >20–<30 mL/min and 22 patients had missing CrCl data in COVERS; 4 patients had CrCl ≤30 mL/min in CANVAS 1 
and 2. 
bSystemic signs were fever >38°C, hypothermia <36°C, elevated WBC count (>10,000 cells/mm3), or bands >10%. 
cSevere local signs were erythema, swelling, tenderness, or warmth that was designated as “severe” by the investigator. 
dSystemic inflammatory response syndrome criteria were defined as presence of ≥2 of the following symptoms at baseline: temperature <36°C or 
>38°C; heart rate >90 beats per minute; respiratory rate >20 breaths per minute, or on blood gas, a PaCO2, <32 mmHg (4.3 kPa); WBCs <4000 
cells/mm3 or >12,000 cells/mm3, or >10% band forms (immature WBC). 
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Table 2 
Susceptibility of Pathogens Isolated at Baseline to Ceftaroline (mMITT population) 
 
COVERS  CANVAS 1 and 2 
Pathogen 
Isolates 
(n) MIC rangea MIC90a,b  Isolates (n) MIC rangea MIC90a 
Gram-positive        
Staphylococcus aureusc 217 0.06–1 0.5  399 0.06–2 0.5 
MSSA 164 0.06–0.5 0.25  235 0.06–0.5 0.25 
MRSA 54 0.25–1 0.5  164 0.25–2 0.5 
Streptococci         
Streptococcus pyogenesd 25 ≤0.008 ≤0.008  61 ≤0.004–0.008 ≤0.004 
Streptococcus agalactiaed 16 ≤0.008–0.015 0.015  22 0.008–0.015 0.015 
Streptococcus dysgalactiae 12 ≤0.008–0.06 0.015  13 ≤0.004–0.008 0.008 
Streptococcus anginosus 
group 
21 ≤0.008–0.03 0.03  14 ≤0.004–0.06 0.03 
Enterococcus faecalis 13 0.5–64 8  27 0.25–16 8 
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Gram-negativee        
Escherichia coli (non−ESBL-
producing) 
26 ≤0.015–8 1  23 0.015–>16 1 
Klebsiella oxytoca 8 0.03–0.25 –  11 0.03–0.25 0.25 
Klebsiella pneumoniae 12 0.06–>32 >32  18 0.03–>16 >16 
Morganella morganii 7 0.03–0.12 –  11 0.06–>16 >16 
Proteus mirabilis 11 0.03–>32 0.12  16 ≤0.008–>16 >16 
ESBL=extended-spectrum beta lactamase; MIC=minimum inhibitory concentration; MRSA=methicillin-resistant S. aureus; MSSA=methicillin-
susceptible S. aureus.  
aMIC range/MIC90 expressed in mg/L. 
bMIC90 not calculated when n<10. 
cFDA/CLSI ceftaroline susceptible/resistant breakpoints ≤1/≥4 mg/L. 
 
dFDA/CLSI ceftaroline susceptible breakpoint ≤0.5 mg/L. 
 
eFDA/CLSI ceftaroline susceptible/resistant breakpoint for Enterobacteriaceae ≤0.5/≥2 mg/L [37]. 
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Table 3 
Clinical Cure Rates at Test-of-Cure Overall and Among Subgroups of Patients with Systemic Signs of Infection, SIRS, and BMI and 
baseline CrCl categories (MITT Population) 
 COVERS  CANVAS 1 and 2 
 
Ceftaroline 
Fosamil 
n/N (%) 
Vancomycin Plus 
Aztreonam 
n/N (%) 
  
Ceftaroline 
Fosamil 
n/N (%) 
Vancomycin Plus 
Aztreonam 
n/N (%) 
 
Patient Population 
Between-Group 
Difference 
(95% CI)  
Between-Group 
Difference 
(95% CI) 
Overall 396/506 (78.3) 202/255 (79.2) –1.0 
(–6.9 to 5.4) 
 595/693 (85.9) 586/685 (85.5) 0.3 
(−3.4 to 4.0) 
≥1 systemic signa 255/312 (81.7) 137/166 (82.5) –0.8 
(−7.7 to 6.8) 
 335/394 (85.0) 326/379 (86.0) −1.0  
(−6.0 to 4.0) 
≥2 severe signs or 
symptomsb 
259/329 (78.7) 137/165 (83.0) –4.3 
(–11.3 to 3.3) 
 330/372 (88.7) 332/379 (87.6) 1.1  
(−3.6 to 5.8) 
Fever 179/211 (84.8) 104/118 (88.1) –3.3  185/211 (87.7) 181/201 (90.0) −2.4  
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(−10.6 to 4.9) (−8.6 to 3.8) 
Elevated WBCc  177/224 (79.0) 75/104 (72.1) 6.9  
(−2.8 to 17.5) 
 205/246 (83.3) 213/254 (83.9) −0.5  
(−7.1 to 6.0) 
SIRSd 168/199 (84.4) 83/105 (79.0) 5.4 
(−3.5 to 15.2) 
 131/155 (84.5) 140/163 (85.9) −1.4  
(−9.4 to 6.5) 
Baseline C-reactive 
protein, mg/L 
       
≤50 149/178 (83.7) 83/100 (83.0) 0.7 
(–8.0 to 10.5) 
 346/396 (87.4) 333/387 (86.0) 1.3  
(−3.5 to 6.1) 
>50 to ≤150 136/178 (76.4) 67/80 (83.8) –7.4 
(–16.9 to 3.8) 
 156/177 (88.1) 138/166 (83.1) 5.0  
(−2.5 to 12.7) 
>150 105/139 (75.5) 49/68 (72.1) 3.5 
(–8.8 to 16.9) 
 76/98 (77.6) 95/111 (85.6) −8.0  
(−18.9 to 2.5) 
BMI, kg/m2        
<18.5 8/15 (53.3) 6/9 (66.7) −13.3  
(−48.2 to 27.4) 
 11/15 (73.3) 5/7 (71.4) 1.9 
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≥18.5–<25 145/185 (78.4) 67/87 (77.0) 1.37  
(−8.7 to 12.7) 
 201/238 (84.5) 182/223 (81.6) 2.8  
(−4.0 to 9.8) 
≥25–<30 115/153 (75.2) 71/86 (82.6) −7.4  
(−17.5 to 3.8) 
 197/216 (91.2) 210/227 (92.5) −1.3  
(−6.7 to 3.9) 
≥30 125/148 (84.5) 58/73 (79.5) 5.01  
(−5.3 to 16.9) 
 186/222 (83.8) 188/227 (82.8) 1.0  
(−6.0 to 7.9) 
CrCl, mL/mine        
>30–≤50 23/31 (74.2) 10/17 (58.8) 15.37  
(-11.61 to 42.57) 
 19/23 (82.6) 21/26 (80.8) 1.8 
(−21.5 to 24.2) 
>50–≤80 71/91 (78.0) 38/46 (82.6) −4.6 
 (−17.6 to 10.7) 
 83/99 (83.8) 88/98 (89.8) −6.0 
(−15.8 to 3.7) 
>80 288/362 (79.6) 149/183 (81.4) −1.9 
(−8.6 to 5.5) 
 492/569 (86.5) 475/559 (85.0) 1.5 
(−2.6 to 5.6) 
BMI=body mass index; SIRS=systemic inflammatory response; WBC=white blood cell. 
aSystemic signs were fever >38°C, hypothermia <36°C, elevated WBC count (>10,000 cells/mm3), or bands >10%. 
bSevere local signs were erythema, swelling, tenderness, or warmth that was designated as “severe” by the investigator. 
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c>10,000 cells/mm3. 
dSystemic inflammatory response syndrome criteria were defined as presence of ≥2 of the following symptoms at baseline: temperature <36°C or 
>38°C; heart rate >90 beats per minute; respiratory rate >20 breaths per minute, or on blood gas, a PaCO2, <32 mmHg (4.3 kPa); WBCs <4000 
cells/mm3 or >12,000 cells/mm3, or >10% band forms (immature WBC). 
eCeftaroline fosamil dosage regimens were adjusted for patients with CrCl >30-≤50 mL/min. Clinical cure rates for patients with CrCl >20–<30 
mL/min (n=8) and patients with missing CrCl data (n=22) in COVERS not shown. 
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Table 4 
Clinical Cure Rate by Baseline Pathogen (ME Population)  
 
COVERS  CANVAS 1 and 2 
Pathogen 
Ceftaroline 
Fosamil 
n/N (%) 
Vancomycin Plus 
Aztreonam 
n/N (%) 
Between-Group 
Difference 
(95% CI)  
Ceftaroline 
Fosamil 
n/N (%) 
Vancomycin Plus 
Aztreonam 
n/N (%) 
Between-Group 
Difference 
(95% CI) 
Gram-positive        
Staphylococcus aureusa 109/119 (91.6) 61/71 (85.9) 5.7 
(–3.3 to 16.5) 
 352/378 (93.1) 336/356 (94.4) −1.3 
(–4.9 to 2.4) 
MSSA 88/94 (93.6) 49/57 (86.0) 7.7 (–1.9 to 19.7)  212/228 (93.0) 22/238 (94.5) 
 
–1.6 
(–6.3 to 2.9) 
MRSA 21/25 (84.0) 12/15 (80.0) 4.0 
(–19.8 to 32.2) 
 142/152 (93.4) 115/122 (94.3) –0.9 
 (–7.0 to 5.5) 
Streptococci        
Streptococcus 
pyogenes 
14/15 (93.3) 7/7 (100) –6.7 
(–30.5 to 30.8) 
 56/56 (100) 56/58 (96.6) 3.9 
(–2.3 to 12.6) 
Streptococcus 5/6 (83.3) 7/9 (77.8) 5.6  21/22 (95.5) 18/18 (100) N/A 
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agalactiae (–41.2 to 44.9) 
Streptococcus 
dysgalactiae 
9/9 (100.0) 0/0 (0) N/A  13/13 (100) 15/16 (93.8) N/A 
Streptococcus 
anginosus group 
16/18 (88.9) 4/4 (100) –11.1 
(–33.4 to 40.6) 
 12/13 (92.3) 15/16 (93.8) N/A 
Enterococcus faecalis 4/6 (66.7) 4/5 (80.0) –13.3 
(–59.6 to 41.6) 
 20/25 (80.0) 22/24 (91.7) –12.6 
(–34.1 to 8.0) 
Gram-negative        
Escherichia coli  11/12 (91.7) 9/10 (90.0) 1.7 
(–28.5 to 34.7) 
 20/21 (95.2) 19/21 (90.5) N/A 
Klebsiella oxytoca 4/4 (100.0) 1/1 (100) N/A  10/12 (83.3) 6/6 (100) N/A 
Klebsiella pneumoniae 5/7 (71.4) 3/4 (75.0) –3.6 
(–51.1 to 52.1) 
 17/18 (94.4) 13/14 (92.9) N/A 
Morganella morganii 4/4 (100) 2/2 (100) N/A  11/12 (91.7) 5/6 (83.3) N/A 
Proteus mirabilis 6/7 (85.7) 2/2 (100) –14.3 
(–53.5 to 58.4) 
 10/15 (66.7) 20/21 (95.2) N/A 
ESBL=extended-spectrum beta lactamase; ME=medically evaluable; MIC=minimum inhibitory concentration; MRSA=methicillin-
resistant S. aureus; MSSA=methicillin-susceptible S. aureus; N/A=not applicable. 
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aPatients with MRSA and MSSA were counted only once. 
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Figure Legend 
Figure 1. Comparison of predicted steady-state ceftaroline fosamil exposures (AUCss and Cmax,ss) in individual ABSSSI patients from 
COVERS (A) with and without SIRS (B) with and without fever (C) with and without high CRP (D) with and without high WBC 
count and (E) with and without bacteremia. ABSSSI=acute bacterial skin and skin structure infections, CRP=C-reactive protein, 
SIRS=systemic inflammatory response syndrome. 
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